Document is current
Any future updates will be listed below
-
Authors
Ishizawa, Kenichi
Yamamoto, Kazuhito
- License Information
-
More Information
Article History
Received: 4 February 2025
Revised: 4 February 2025
Accepted: 25 February 2025
First Online: 24 March 2025
Declarations
:
: KI has received per diem, including speaking fees, from Takeda Pharmaceuticals, Novartis Pharma, Janssen Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical, Sanofi, Bristol Myers Squibb, MSD, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, IQVIA Services Japan, Micron, and Sawai Pharmaceutical; and has received research funding from Otsuka Pharmaceutical, Pfizer, SymBio Pharmaceuticals, AbbVie, Sanofi, Novartis Pharma, Chugai Pharmaceutical, IQVIA Services Japan, and Zenyaku Kogyo. KY has received per diem, including speaking fees, from AbbVie, IQVIA Services Japan/HUYA Bioscience International, Eisai, Chugai Pharmaceutical, Meiji Seika Pharma, Micron/Daiichi Sankyo, and Janssen Pharmaceutical; and has received research funding from IQVIA Services Japan/Genmab, IQVIA Services Japan/Incyte Biosciences Japan, and Yakult Honsha.
